Brief: Overall Survival Primary Endpoint Met In Corcept’S Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated

22/01/2026 13:19

Jan 22 (Reuters) - Corcept Therapeutics Inc CORT.O:

OVERALL SURVIVAL PRIMARY ENDPOINT MET IN CORCEPT’S PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

CORCEPT THERAPEUTICS INC - DATA SHOW 35% REDUCTION IN RISK OF DEATH

CORCEPT THERAPEUTICS INC - PHASE 3 ROSELLA TRIAL MEETS OVERALL SURVIVAL ENDPOINT

Source text: ID:nBw7FR5S1a

Further company coverage: CORT.O

 ((Reuters.Briefs@thomsonreuters.com;))